A phase II study evaluating tipifarnib in HRAS-mutant squamous NSCLC (NCT03496766) and another phase II study of tipifarnib in HNSCC with HRAS mutations are ongoing (NCT02383927). The gene discussed is HRAS; the disease is head and neck squamous cell carcinoma.